留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响

杨丽萍 吴爱林 周燕 陶振超 何健 杨婧 张洋洋 钱立庭 高劲

杨丽萍, 吴爱林, 周燕, 陶振超, 何健, 杨婧, 张洋洋, 钱立庭, 高劲. 放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响[J]. 中华全科医学, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622
引用本文: 杨丽萍, 吴爱林, 周燕, 陶振超, 何健, 杨婧, 张洋洋, 钱立庭, 高劲. 放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响[J]. 中华全科医学, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622
YANG Li-ping, WU Ai-lin, ZHOU Yan, TAO Zhen-chao, HE Jian, YANG Jing, ZHANG Yang-yang, QIAN Li-ting, GAO Jin. Effect of NLR and PLR from pre-radiotherapy on prognosis of locally advanced nasopharyngeal carcinoma patients[J]. Chinese Journal of General Practice, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622
Citation: YANG Li-ping, WU Ai-lin, ZHOU Yan, TAO Zhen-chao, HE Jian, YANG Jing, ZHANG Yang-yang, QIAN Li-ting, GAO Jin. Effect of NLR and PLR from pre-radiotherapy on prognosis of locally advanced nasopharyngeal carcinoma patients[J]. Chinese Journal of General Practice, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622

放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响

doi: 10.16766/j.cnki.issn.1674-4152.002622
基金项目: 

国家自然科学基金青年科学基金项目 11805198

详细信息
    通讯作者:

    高劲, E-mail: gj11667@126.com

  • 中图分类号: R739.2 R730.7

Effect of NLR and PLR from pre-radiotherapy on prognosis of locally advanced nasopharyngeal carcinoma patients

  • 摘要:   目的  探讨放疗前血液中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)及血小板与淋巴细胞比值(platelet-lymphocyte ratio,PLR)与局部晚期鼻咽癌放疗患者预后的相关性。  方法  回顾性分析2016年1月—2018年12月在中国科学技术大学附属第一医院头颈放疗科行放化疗的60例局部晚期鼻咽癌患者临床资料及随访资料,采用ROC曲线确定NLR和PLR的最佳截断值,并据此分为高水平组和低水平组。采用χ2检验或Fisher精确检验比较组间差异,使用Kaplan-Meier法绘制生存曲线,采用Cox回归模型进行多因素分析。  结果  依据ROC曲线,放疗前NLR和PLR的最佳截取值分别为1.99、154.94。在单因素分析中N分期、临床分期、放疗前NLR及PLR与患者预后相关(均P<0.05);放疗前低NLR组的生存时间为(62.26±1.88)个月,优于放疗前高NLR组[(51.17±3.94)个月,P=0.048];相较于放疗前高PLR组,放疗前低PLR组生存时间更长(P=0.014);而Cox多因素分析中临床分期、N分期、放疗前PLR水平是影响局部晚期鼻咽癌患者生存的独立预后因素(均P<0.05)。  结论  放疗前PLR水平可作为局部晚期鼻咽癌放疗患者独立预后预测因子,推荐其作为辅助手段参与患者预后评估。

     

  • 图  1  放疗前NLR与OS关系的ROC曲线

    Figure  1.  ROC curve of the relationship between NLR and OS before radiotherapy

    图  2  放疗前PLR与OS关系的ROC曲线

    Figure  2.  ROC curve of the relationship between PLR and OS before radiotherapy

    图  3  放疗前NLR高表达组与低表达组OS曲线比较

    Figure  3.  Comparison of OS curves between high and low NLR expression groups before radiotherapy

    图  4  放疗前PLR高表达组与低表达组OS曲线比较

    Figure  4.  Comparison of OS curves between high and low PLR expression groups before radiotherapy

    表  1  放疗前NLR与局部晚期鼻咽癌患者临床特征的关系

    Table  1.   Relationship between NLR and clinical characteristics of patients with locally advanced nasopharyngeal carcinoma before radiotherapy

    组别 例数 性别[例(%)] 年龄(x±s, 岁) T分期[例(%)] N分期[例(%)] 临床分期[例(%)] EB-PCR[例(%)]
    男性 女性 T2 T3~4 N0~N2 N3 Ⅲ期 Ⅳa+Ⅳb期 阴性 阳性
    高NLR组 29 23(79.3) 6(20.7) 52.07±11.17 2(6.9) 27(93.1) 26(89.7) 3(10.3) 14(48.3) 15(51.7) 18(62.1) 11(37.9)
    低NLR组 31 21(67.7) 10(32.3) 48.36±10.93 7(22.6) 24(77.4) 25(80.6) 6(19.4) 20(64.5) 11(35.5) 22(71.0) 9(29.0)
    统计量 1.025a 0.065b 3.547a 0.954a 1.609a 0.534a
    P 0.311 0.800 0.199 0.474 0.157 0.324
    注:a为χ2值,bt值。
    下载: 导出CSV

    表  2  放疗前PLR与局部晚期鼻咽癌患者临床特征的关系

    Table  2.   Relationship between PLR and clinical features in patients with locally advanced nasopharyngeal carcinoma before radiotherapy

    组别 例数 性别[例(%)] 年龄(x±s, 岁) T分期[例(%)] N分期[例(%)] 临床分期[例(%)] EB-PCR[例(%)]
    男性 女性 T2 T3~4 N0~N2 N3 Ⅲ期 Ⅳa+Ⅳb期 阴性 阳性
    高PLR组 10 6(60.0) 4(40.0) 53.90±8.67 2(20.0) 8(80.0) 8(80.0) 2(20.0) 3(30.0) 7(70.0) 8(80.0) 2(20.0)
    低PLR组 50 38(76.0) 12(24.0) 49.40±11.48 7(14.0) 43(86.0) 43(86.0) 7(14.0) 31(62.0) 19(38.0) 32(64.0) 18(36.0)
    统计量 1.091a 0.655b 2.290a 0.235a 3.475a 0.960a
    P 0.433 0.422 0.254 0.637 0.085 0.471
    注:a为χ2值,bt值。
    下载: 导出CSV

    表  3  影响局部晚期鼻咽癌患者预后的单因素分析

    Table  3.   Univariate analysis of prognosis in patients with locally advanced nasopharyngeal carcinoma

    项目 例数 生存时间(x±s, 月) 5年生存率(%) Wald χ2 P
    性别 0.188 0.664
      男性 44 56.36±2.55 86.4
      女性 16 56.38±4.52 81.3
    年龄 1.307 0.253
       < 50岁 30 60.53±2.45 90.0
      ≥50岁 30 53.13±3.64 80.0
    T分期 0.165 0.685
      T2 9 55.11±3.67 88.9
      T3~4 51 57.14±2.58 84.3
    N分期 8.288 0.004
      N0~N2 51 60.31±2.00 90.2
      N3 9 40.78±8.12 55.6
    临床分期 5.138 0.023
      Ⅲ期 34 62.24±1.90 94.1
      Ⅳa+Ⅳb期 26 50.15±4.22 73.1
    EB-PCR 0.527 0.468
      阴性 40 56.15±2.46 87.5
      阳性 20 55.35±4.39 80.0
    放疗前NLR 3.912 0.048
      低NLR组 31 62.26±1.88 93.5
      高NLR组 29 51.17±3.94 75.9
    放疗前PLR 5.985 0.014
      低 10 60.20±2.13 90.0
      高 50 36.10±5.21 60.0
    下载: 导出CSV

    表  4  影响局部晚期鼻咽癌患者预后的多因素Cox回归分析

    Table  4.   Multivariate Cox regression analysis of prognostic factors in patients with locally advanced nasopharyngeal carcinoma

    变量 B SE Wald χ2 P HR 95% CI
    临床分期 -1.458 0.668 4.770 0.029 0.233 0.063~0.861
    N分期 -1.252 0.621 4.066 0.044 0.286 0.085~0.966
    放疗前NLR -1.453 0.802 3.279 0.070 0.234 0.049~1.127
    放疗前PLR -1.680 0.617 7.048 0.006 0.186 0.056~0.625
    注:各变量赋值方法,临床分期,Ⅲ期=1,Ⅳa+Ⅳb期=2;N分期,N0~N2期=1,N3期=2;NLR、PLR均以实际值赋值。
    下载: 导出CSV
  • [1] YANG L P, GAO J, ZHOU Y, et al. Prognostic value of the albumin-to-alkaline phosphatase ratio before chemoradiotherapy in patients with nonmetastatic nasopharyngeal carcinoma[J]. Chemotherapy, 2021, 66(1-2): 40-46. doi: 10.1159/000513058
    [2] SUN X S, LIANG Y J, LIU S L, et al. Subdivision of nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis for prediction of survival and treatment guidance[J]. Cancer Res Treat, 2019, 51(4): 1259-1268. doi: 10.4143/crt.2018.652
    [3] LIU S L, SUN X S, LU Z J, et al. Nomogram predicting the benefits of adding concurrent chemotherapy to intensity-modulated radiotherapy after induction chemotherapy in Stages Ⅱ-Ⅳb nasopharyngeal carcinoma[J]. Front Oncol, 2020, 9(10): 539321. DOI: 10.3389/fonc.2020.539321.
    [4] QIU W Z, KE L R, XIA W X, et al. A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy[J]. PLoS One, 2017, 12(8): e0182963. DOI: 10.1371/journal.pone.0182963.
    [5] XIANG Z J, HU T, WANG Y, et al. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)[J]. Biosci Rep, 2020, 40(6): BSR20201190. DOI: 10.1042/BSR20201190.
    [6] 刘建辉, 罗妍, 陈晓, 等. 放疗前中性粒细胞/淋巴细胞血小板/淋巴细胞预后营养指数及CA199与胰腺腺癌放疗后预后关系的分析[J]. 中国肿瘤临床, 2017, 44(6): 289-293. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201706011.htm

    LIU J H, LUO Y, CHEN X, et al. Pre-radiation neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, prognostic nutritional index, and CA19-9 as prognostic factors in pancreatic cancer patients treated with radiotherapy[J]. Chinese Journal of Clinical Oncology, 2017, 44(6): 289-293. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201706011.htm
    [7] 汪庚明, 周燕, 孙谦, 等. 局部晚期下咽癌患者放疗前NLR与PLR对预后的意义[J]. 中华全科医学, 2021, 19(5): 763-766. doi: 10.16766/j.cnki.issn.1674-4152.001911

    WANG G M, ZHOU Y, SUN Q, et al. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with locally advanced hypopharyngeal cancer treated with radiation[J]. Chinese Journal of General Practice, 2021, 19(5): 763-766. doi: 10.16766/j.cnki.issn.1674-4152.001911
    [8] 郭苗, 刘玮, 李伟. FIB、NLR、PLR联合检测在非小细胞肺癌早期诊断及预后评估中的价值[J]. 海南医学, 2020, 31(15): 1954-1957. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIN202015014.htm

    GUO M, LIU W, LI W. Value of combined detection with FIB, NLR, and PLR in the early diagnosis and prognosis evaluation of non-small cell lung cancer[J]. Hainan Medical Journal, 2020, 31(15): 1954-1957. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIN202015014.htm
    [9] 杨洁, 王晨, 徐庆春, 等. 结直肠癌患者术前NLR、PLR、PDW与其预后的关系[J]. 山东医药, 2018, 58(24): 61-63. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201824018.htm

    YANG J, WANG C, XU Q C, et al. Relationship between preoperative NLR, PLR, PDW and prognosis in patients with colorectal cancer[J]. Shandong Medical Journal, 2018, 58(24): 61-63. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201824018.htm
    [10] XIA Z F, HU D F, XIONG H C, et al. Benefit of chemotherapy in stage Ⅲ nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database[J]. Oral Oncol, 2021, 117: 105284. DOI: 10.1016/j.oraloncology.2021.105284.
    [11] LI X, GAO Y, XU Z, et al. Identification of prognostic genes in adrenocortical carcinoma microenviron-ment based on bioinformatic methods[J]. Cancer Med, 2020, 9(3): 1161-1172. doi: 10.1002/cam4.2774
    [12] WANG D, BAI N, HU X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J]. PeerJ, 2019, 7: e7132. DOI: 10.7717/peerj.7132.
    [13] GUO W Y, LU X, LIU Q P, et al. Prognostic value of neutrophil-to-lymphocyte ratio and plateletto-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals[J]. Cancer Med, 2019, 8(9): 4135-4148. doi: 10.1002/cam4.2281
    [14] LIU C X, LI X L. Stage-dependent changes in albumin, NLR, PLR, and AFR are correlated with shorter survival in patients with gastric cancer[J]. Clin Lab, 2019, 65(9): e31532095. DOI: 10.7754/Clin.Lab.2019.190132.
    [15] CHEN C J, YANG H T, CAI D, et al. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR)and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(2): 866-877. doi: 10.21037/tlcr-20-997
    [16] MECHTELD C, RADU MH, SHAHAB K H. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as possible prognostic markers for patients undergoing resection of adrenocortical carcinoma[J]. World J Surg, 2021, 45(3): 754-764.
    [17] 金龙, 付神波, 于娇. 治疗前PLR和NLR对鼻咽癌患者预后的影响[J]. 肿瘤防治研究, 2017, 44(7): 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY201707006.htm

    JIN L, FU S B, YU J. Effect of NLR and PLR from pre-treatment on prognosis of nasopharyngeal carcinoma patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY201707006.htm
    [18] 张东成, 汪浩. NLR/PA、NLR/Alb和NLR在食管鳞癌根治性放疗近期疗效预测中的价值[J]. 山东医药, 2020, 60(25): 66-68. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202025018.htm

    ZHANG D C, WANG H. Value of NLR/PA, NLR/Alb and NLR in predicting short-term response to radical radiotherapy for esophageal squamous cell carcinoma[J]. Shandong Medical Journal, 2020, 60(25): 66-68. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202025018.htm
    [19] SILVA R N F, DALLARMI L B, ARAUJO A K C, et al. Immunohisto-chemical analysis of neutrophils, interleukin-17, matrix metal-loproteinase-9, and new formed vessels in oral squamous cellcarcinoma[J]. J Oral Pathol Med, 2018, 47(9): 856-863.
    [20] LI Z L, QU Y, YANG Y, et al. Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma[J]. Clin Otolaryngol, 2021, 46(2): 395-405.
    [21] LU A Y, LI H F, ZHENG Y M, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma[J]. Biomed Res Int, 2017, 2017: 3047802. DOI: 10.1155/2017/3047802.
  • 加载中
图(4) / 表(4)
计量
  • 文章访问数:  216
  • HTML全文浏览量:  94
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-25
  • 网络出版日期:  2022-11-29

目录

    /

    返回文章
    返回